Company Profile
Praxis Precision Medicines Stock Price, News & Analysis
- Ticker:
- PRAX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
315.80 USD (-2.92%)
Close
Last updated: July 27, 2026
7.19B USD
Market cap
Why the stock is moving
As of Jul 27, 2026, PRAX closed down 2.92% at $315.80. No new same-company headline was identified in the current news window.
Company overview
Business overview
Praxis Precision Medicines is a neuroscience company focused on precision approaches to brain disease and movement disorders. Its platform aims to translate genetics and neurobiology into treatment options.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Praxis sits in specialty neuroscience biotechnology.
Business Model Characteristics
The company depends on clinical validation, target biology, and the ability to build a differentiated CNS franchise.
Position Within the Biotechnology Landscape
Praxis is a high-catalyst neuroscience name whose valuation is closely tied to early trial outcomes.
Future catalysts
Praxis now has two late-stage programs that can change the tone of the company. Ulixacaltamide in essential tremor and relutrigine in the DEE indications both sit close enough to launch planning that the next updates will feel much more concrete than generic pipeline language.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman
BCLI · Source: Brainstorm Cell Therapeutics Inc.
- 02
Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026
DNLI · Source: Denali Therapeutics
- 03
Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026
TNXP · Source: Tonix Pharmaceuticals
- 04
Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
IKT · Source: Inhibikase Therapeutics
- 05
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
KTTA · Source: Pasithea Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Praxis Precision Medicines (PRAX)?
Praxis Precision Medicines (PRAX) most recently closed at 315.80 USD, a -2.92% move versus the previous session.
What is the market cap of Praxis Precision Medicines (PRAX)?
Praxis Precision Medicines currently has a market capitalization of 7.19B USD on BioPharmSignal.
What does Praxis Precision Medicines do?
Praxis Precision Medicines is a neuroscience company focused on precision approaches to brain disease and movement disorders. Its platform aims to translate genetics and neurobiology into treatment options.
On which exchange is PRAX stock listed?
Praxis Precision Medicines (PRAX) is associated with NASDAQ, United States, Biopharma.
What is Praxis?
Praxis now has two late-stage programs that can change the tone of the company.
Which conditions is Praxis Precision Medicines targeting with Praxis?
Praxis Precision Medicines is associated with neuroscience, genetic disease based on its company overview and current catalyst commentary.
How does Praxis Precision Medicines describe recent progress with Praxis?
Praxis now has two late-stage programs that can change the tone of the company.
What is Precision?
Praxis Precision Medicines is a neuroscience company focused on precision approaches to brain disease and movement disorders.